Mark Wilterding | VP, IR |
Michael Mussallem | Chairman & CEO |
Scott Ullem | Corporate VP & CFO |
Bernard Zovighian | Corporate VP, Transcatheter Mitral & Tricuspid Therapies |
Daveen Chopra | Corporate VP, Surgical Heart Valve Therapies |
Larry Wood | Corporate VP, Transcatheter Aortic Valve Replacement |
Lawrence Biegelsen | Wells Fargo Securities |
Robert Marcus | JPMorgan Chase & Co. |
Joshua Jennings | Cowen and Company |
Joanne Wuensch | Citigroup |
Richard Newitter | Truist Securities |
Frederick Wise | Stifel, Nicolaus & Company |
Cecilia Furlong | Morgan Stanley |
Philip Chickering | Deutsche Bank |
Vijay Kumar | Evercore ISI |
Travis Steed | Bank of America Merrill Lynch |
Adam Maeder | Piper Sandler & Co. |
Good afternoon, and welcome to the Edwards Lifesciences Third Quarter 2022 Results Conference Call. [Operator Instructions]. Please note that this conference is being recorded. I will now turn the conference over to our host, Mark Wilterding, Senior Vice President, Investor Relations and Treasurer. Thank you.